Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: A pilot study

Clinical Drug Investigation

Volumn 27, Issue 12, 2007, Pages 827-832

  Fei, Luo ^a   Golwa, Filimon ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral vasospasm; Dexamethasone, therapeutic use; Subarachnoid haemorrhage; Topical

Indexed keywords

DEXAMETHASONE;

ADULT; ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN BLOOD FLOW; BRAIN VASOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE CEREBRAL ARTERY; POSTOPERATIVE CARE; PRIORITY JOURNAL; STUDENT T TEST; SUBARACHNOID HEMORRHAGE;

EID: 36348961838     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727120-00004     Document Type: Article

References (35)

1. Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modiies fied fisher scale. Neurosurg 2006; 59: 21-7
2. Pasqualin A. Epidemiology and pathophysiology of cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg Sci 1998;42: 15-21
3. Nagata K, Sasaki T, Mori T, et al. Cisternal talc injection in dog can induce delayed and prolonged arterial constriction resembling cerebral vasospasm morphologically and pharmacologically. Surg Neurol 1996 May; 45 (5): 442-7
4. Hirashima Y, Endo S, Otsuji T, et al. Platelet-activating factor and cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 1993 Apr; 78 (4): 592-7
5. Hirashima Y, Endo S, Ohmori T, et al. Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage. J Neurosurg 1994 Jan; 80 (1): 31-6
6. Abe Y, Kasuya H, Suzuki S, et al. Effect of a platelet-activating factor antagonist, E5880, on cerebrovasospasm following subarachnoid hemorrhage in a canine double-hemorrhage model. Eur J Pharmacol 2002 Nov 29; 455 (2-3): 127-33
7. Hirashima Y, Endo S, Kato R, et al. Prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by the platelet-activating factor antagonist, E5880. J Neurosurg 1996 May; 84 (5): 826-30
8. Hirashima Y, Nakamura S, Endo S, et al. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997 Oct; 22 (10): 1249-55
9. Bowman G, Dixit S, Bonneau RH, et al. Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery 2004 Mar; 54 (3): 719-25; discussion 25-6
10. Bowman G, Bonneau RH, Chinchilli VM, et al. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocrit Care 2006; 5 (3): 222-9
11. Satoh M, Date I, Nakajima M, et al. Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke 2001 Jan; 32 (1): 225-31
12. Recinos PF, Pradilla G, Thai QA, et al. Controlled release of lipopolysaccharide in the subarachnoid space of rabbits induces chronic vasospasm in the absence of blood. Surg Neurol 2006 Nov; 66 (5): 463-9; discussion 9
13. Zhou ML, Shi JX, Hang CH, et al. Potential contribution of nuclear factor-kappaB to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. J Cereb Blood Flow Metab. In press
14. Asaeda M, Sakamoto M, Kurosaki M, et al. A non-enzymatic derived arachidonyl peroxide, 8-iso-prostaglandin F2 alpha, in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. Neurosci Lett 2005 Jan 20; 373 (3): 222-5
15. Sasaki T, Kasuya H, Onda H, et al. Role of p38 mitogen-activated protein kinase on cerebral vasospasm after subachnoid hemorrhage. Stroke 2004 Jun; 35 (6): 1466-70
16. Zhang Z, Nagata I, Kikuchi H, et al. Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke 2001 Jul; 32 (7): 1665-72
17. Nakamura S, Tsubokawa T, Yoshida K, et al. Appearance of collagen fibers in the cerebral vascular wall following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1992 Nov; 32 (12): 877-82
18. Macdonald RL, Zhang ZD, Ono S, et al. Up-regulation of parathyroid hormone receptor in cerebral arteries after subarachnoid hemorrhage in monkeys. Neurosurgery 2002 May; 50 (5): 1083-91; discussion 91-3
19. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000 Dec; 31 (12): 2971-5
20. Aihara Y, Kasuya H, Onda H, et al. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage. Stroke 2001 Jan; 32 (1): 212-7
21. Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999 Nov; 19 (11): 1279-88
22. Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003 Aug; 99 (2): 376-82
23. Yatsushige H, Yamaguchi M, Zhou C, et al. Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke 2005 Jul; 36 (7): 1538-43
24. Chyatte D. Prevention of chronic cerebral vasospasm in dogs with ibuprofen and high-dose methylprednisolone. Stroke 1989 Aug; 20 (8): 1021-6
25. Pradilla G, Thai QA, Legnani FG, et al. Local delivery of ibuprofen via controlled-release polymers prevents angioduces graphic vasospasm in a monkey model of subarachnoid hemorrhage. Neurosurgery 2005 Jul; 57 (1 Suppl): 184-90; discussion 90
26. Thai QA, Oshiro EM, Tamargo RJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke 1999 Jan; 30 (1): 140-7
27. Chyatte D, Rusch N, Sundt Jr TM. Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. J Neurosurg 1983 Dec; 59 (6): 925-32
28. Chyatte D, Fode NC, Nichols DA, et al. Preliminary report: subaracheffects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1987 Aug; 21 (2): 157-60
29. Chyatte D, Sundt Jr TM. Response of chronic experimental cerebral vasospasm to methylprednisolone and dexamethasone. J Neurosurg 1984 May; 60 (5): 923-6
30. Kim CJ, Bassiouny M, Macdonald RL, et al. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Stroke 1996 Sep; 27 (9): 1629-33
31. Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 1998 Sep; 29 (9): 1930-5; discussion 5-6
32. Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 2001 Jul; 95 (1): 44-50
33. Auer LM, Ito Z, Suzuki A, et al. Prevention of symptomatic vasospasm by topically applied nimodipine. Acta Neurochir (Wien) 1982; 63 (1-4): 297-302
34. Welty TE. Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage. Clin Pharm 1987 Dec; 6 (12): 940-6
35. Schurkamper M, Medele R, Zausinger S, et al. Dexamethasone in the treatment of subarachnoid hemorrhage revisited: a comantibody parative analysis of the effect of the total dose on complicaorrhage tions and outcome. J Clin Neurosci 2004 Jan; 11 (1): 20-4